# ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

> **NCT02091063** · PHASE1,PHASE2 · TERMINATED · sponsor: **Jennifer Amengual** · enrollment: 23 (actual)

## Conditions studied

- Lymphoma
- Lymphoid Malignancies

## Interventions

- **DRUG:** ACY-1215

## Key facts

- **NCT ID:** NCT02091063
- **Lead sponsor:** Jennifer Amengual
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-02
- **Primary completion:** 2019-02-25
- **Final completion:** 2019-05-05
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091063, "ACY-1215 for Relapsed/Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02091063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*